Fertilization promoting peptide (FPP; pGlu-Glu-ProNH 2 ) is structurally similar to thyrotrophin releasing hormone (TRH; pGlu-His-ProNH 2 ) and so crossreacts with antibodies to TRH. TRH-like material was found in mammalian prostate glands and semen by Pekary et al. in the early 1980s (1980 Pekary et al. in the early 1980s ( , 1983 but it was not until 1989 that FPP was isolated from the rabbit prostate complex, characterized and shown to be distinct from TRH (Cockle et al., 1989) . Subsequent studies have identified FPP in the prostate gland and semen of several other mammals, including humans and various rodents (Cockle, 1995) , and in the pituitary glands of both birds and mammals (Ashworth et al., 1993; Harvey et al., 1993; Rondeel et al., 1993) . At present, no specific function for pituitary-derived FPP in vivo has been demonstrated, but evidence is accumulating that prostatederived FPP may play an important role relating to sperm function in vivo.
Production of FPP appears to be under androgen control since its appearance in the rabbit prostate coincides with the surge of androgens at the onset of puberty (Thetford et al., 1992) . The relatively high concentration of FPP in seminal plasma (mean of approximately 50 nmol l -1 in humans; Cockle et al., 1994) suggested a possible role relating to spermatozoa. Studies by Green et al. (1994) have provided evidence that FPP does indeed have biologically important effects on spermatozoa and for this reason it has been called 'fertilization promoting peptide'.
It is useful here to summarize the requirements for production of potentially fertilizing spermatozoa in order to appreciate the importance of the proposed roles for FPP. When mammalian spermatozoa are released from the male reproductive tract, they are morphologically complete and capable of independent motility, but they are not physiologically competent, that is, they cannot fertilize oocytes, even when evaluated in vitro. Spermatozoa require a species-dependent period of time in permissive conditions, usually provided in vivo by the female reproductive tract but also supported by appropriate culture media in vitro, to undergo capacitation (physiological 'switching-on') and to become fully functional. Although the requirement for capacitation has been known for over 40 years (see Yanagimachi, 1994) , we still have much to learn about the molecular mechanisms involved. However, there is considerable evidence that certain signal transduction pathways play important roles. In particular, the adenylyl cyclase (AC)/cAMP pathway has been identified as an important participant in capacitation (Fraser and Monks, 1990; deLamirande et al., 1997) . Once capacitated, the spermatozoon is potentially fertilizing. Successful interaction with an unfertilized oocyte will trigger the acrosome reaction, an exocytotic event involving fusion of the sperm plasma and outer acrosomal membranes and release of lytic enzymes, as a prelude to sperm penetration of the zona pellucida. Capacitated spermatozoa can also undergo a spontaneous acrosome reaction but this is tantamount to the Fertilization promoting peptide (FPP; pGlu-Glu-ProNH 2 ), a tripeptide structurally related to thyrotrophin releasing hormone, is produced by the prostate gland and released into seminal plasma. Recent studies carried out in vitro have revealed that FPP elicits biologically important responses in both mouse and human spermatozoa. In the presence of physiological concentrations of FPP (50-100 nmol l -1 ), uncapacitated spermatozoa undergo accelerated capacitation and so become potentially fertilizing more quickly, while capacitated spermatozoa are inhibited from undergoing spontaneous acrosomal exocytosis, an event that would make them non-fertilizing. In vivo, these responses would be very important since relatively few spermatozoa reach the site of fertilization; FPP could help to ensure that these were potentially fertilizing cells. A putative receptor (TCP-11) for FPP has been identified in mice. The gene for TCP-11 (which has a human homologue) maps to the t-complex, a region known to contain genes affecting male fertility. Current evidence indicates that FPP and TCP-11 act by modulating the activity of adenylyl cyclase and hence production of cAMP, a signal transduction pathway shown to be important in the acquisition of fertilizing ability. These results suggest that FPP plays an important role in normal fertility and that insufficient FPP could reduce fertility. Prostatic dysfunction can lead to decreased synthesis of FPP and increased synthesis of FPPrelated peptides with reduced biological activity, both of which could compromise fertility in vivo. Given that 'male factor' infertility is a common contributor to subfertility in couples, it may prove possible to develop new therapeutic treatments, for at least some males, using FPP. In addition, this ligand-receptor pair could provide a novel target for male contraception.
cell committing suicide since acrosome-reacted cells are nonfertilizing, even if highly motile (Yanagimachi, 1994) .
Effects of FPP on spermatozoa
The first studies investigating the effects of FPP on spermatozoa used epididymal mouse spermatozoa because these would not have come into contact with the peptide (Green et al., 1994) . After incubation in the presence of FPP, cells were evaluated using the fluorescent antibiotic chlortetracycline (CTC) and in vitro fertilization (IVF). CTC binds particularly to membraneassociated divalent cations (Caswell and Hutchinson, 1971) , with CTC fluorescence reportedly being more sensitive to Ca 2+ than to Mg 2+ (Hallett et al., 1972) . In mice, changes in the CTC fluorescence patterns reflect the presence or absence of a decapacitation factor and hence reflect changes in the functional state of spermatozoa (Fraser et al., 1990) . Most cytological techniques used to evaluate spermatozoa only identify acrosomeintact and acrosome-reacted spermatozoa, while CTC allows the acrosome-intact category to be subdivided, on the basis of apparent differences in functional state, into uncapacitated and capacitated spermatozoa. Since acrosome-intact, capacitated spermatozoa would be the potentially fertilizing cells, this gives CTC a unique advantage over more commonly used techniques. Results of CTC analysis indicated that FPP, used at physiologically relevant nanomolar concentrations in vitro, significantly stimulated capacitation but not the spontaneous acrosome reaction. In contrast, many other experimental treatments will stimulate both. As predicted from the CTC data, FPP-treated suspensions were significantly more fertile than untreated suspensions (FPP: 56.5% of oocytes fertilized; control: 26.5%) and this was the basis for the proposed name for the peptide (Green et al., 1994) . Subsequent studies (Green et al., 1996a) demonstrated that FPP also stimulated human sperm capacitation (assessed with CTC) and penetrating ability (assessed using the zona-free hamster oocyte penetration test). In addition to acting on uncapacitated spermatozoa, FPP was also observed to have an important effect on capacitated cells: it significantly inhibited the spontaneous acrosome reaction, although cells were still able to undergo the acrosome reaction in response to progesterone (Green et al., 1996b) . In vivo, these effects of FPP could be very important since only capacitated acrosome-intact cells can fertilize; spontaneously acrosome-reacted cells are non-fertilizing. The effects of FPP on spermatozoa are summarized (Table 1) .
Proposed mechanism of action
It is relatively unusual for a single molecular entity to have both stimulatory and inhibitory effects on spermatozoa. However, earlier studies (Stein et al., 1986) had demonstrated that adenosine exerted biphasic effects on the activity of AC and its production of cAMP. Experiments were carried out using adenosine individually and in combination with FPP to test the possibility that FPP and adenosine act on the same pathway. The results indicated that adenosine did indeed elicit the same biphasic responses as FPP (Green et al., 1996b) . Furthermore, when used at either low concentrations (no significant response if used singly) or high concentrations (maximal response), adenosine plus FPP was more effective than either used individually. These responses suggest that FPP and adenosine work on the same signal transduction pathway but use separate receptors. Because adenosine is known to modulate AC/cAMP via specific external receptors (Fraser, 1990; Fraser and Duncan, 1993) , it has been proposed that FPP also modulates the AC/cAMP pathway. This is a plausible proposal since cAMP has been shown to have very important positive effects on sperm capacitation and fertilizing ability (Fraser and Monks, 1990) . Direct evidence that FPP, like adenosine, can significantly stimulate AC production of cAMP in mouse sperm membrane preparations and both permeabilized and intact cells has now been obtained (Adeoya-Osiguwa et al., 1998) .
Further evidence that FPP and adenosine act via different specific receptors has been obtained during the investigation of FPP-related peptides. An increase in neutral peptides and a decrease in FPP have been observed in prostatic tissue from men with prostatic dysfunction (Cockle et al., 1994) . Evaluation of several tripeptides revealed that all have reduced or no biological activity when compared with FPP (Table 2) . One of these peptides was pGlu-Gln-ProNH 2 (Gln-FPP), a neutral peptide (distinct from FPP, which is negatively charged at physiological pH), that has been identified in human seminal plasma (Khan et al., 1992 
Putative FPP receptor
The experimental evidence cited above predicts the existence of an FPP-specific receptor. The identification of a candidate molecule occurred during what began as an apparently unrelated study of TCP-11, the protein product of Tcp-11. Tcp-11, which has a human homologue (Ragoussis et al., 1992) , is a gene that maps to the t-complex on chromosome 17 of the mouse (Mazarakis et al., 1991) , a complex containing genes known to affect male fertility (for recent review see Olds-Clarke, 1997).
Heterozygous male mice with one wild type chromosome 17 and one t-complex containing chromosome 17 transmit the latter to > 90% of their offspring (although the two types of spermatozoa are produced in equal proportions), suggesting that the t-bearing spermatozoa have a functional advantage in vivo. Recent studies of TCP-11 have suggested a possible mechanism whereby a t-complex gene product modulates sperm function. Tcp-11 is only expressed in developing germ cells in the testis, being transcribed late in spermatogenesis and translated during spermiogenesis (Mazarakis et al., 1991; Hosseini et al., 1994) . In mature epididymal spermatozoa, it is found on the surface of both the head and flagellum in very discrete positions: consistently on the acrosomal cap of acrosome-intact but not acrosome-reacted cells and the principal piece of the flagellum, and more variably on the midpiece ( Fig. 1; Fraser et al., 1997b) . When sperm suspensions were incubated in the presence of Fab fragments of a purified IgG fraction of polyclonal anti-TCP-11 antiserum, CTC analysis revealed that capacitation was stimulated after a short incubation (30 min) and spontaneous acrosome loss was inhibited after a longer incubation (120 min). Functional analysis using in vitro fertilization revealed that Fab-treated suspensions became fertile more quickly than untreated control suspensions and then maintained high fertilizing ability, despite inhibition of the spontaneous acrosome reaction (Fraser et al., 1997b) .
The similarity of responses obtained with Fab fragments to TCP-11, FPP and adenosine led to further experimental investigations using these three in various combinations. The results indicated that FPP and Fab fragments were working at the same FPP-specific site, one distinct from the adenosine-specific site. For example, Fab plus adenosine produced a greater response than either used alone, while Gln-FPP inhibited responses to Fab but not to adenosine (Fraser et al., 1997b) .
These results suggest that TCP-11 could be the receptor for FPP. By binding to TCP-11, the Fab fragments are able to act as agonists to modulate a signal transduction pathway linked to TCP-11, the candidate pathway being AC/cAMP. Very recent evidence supports these hypotheses. First, Fab fragments have been shown to inhibit specific binding of [ 3 H]FPP to mouse sperm membranes and to stimulate AC production of cAMP by permeabilized cells (Adeoya-Osiguwa et al., 1998) . Future studies will address more specifically the way in which TCP-11 might interact with AC. Although adenosine receptors have seven membrane spanning regions typical of external receptors that modulate intracellular enzyme activity (Palmer and Stiles, 1995) , TCP-11 has no obvious transmembrane domains (Mazarakis et al., 1991) . It may be that TCP-11 interacts with another molecule that does span the membrane (possibly the adenosine receptor itself) to elicit responses (Fraser and Cliff, 1998) .
Thus, FPP ↔ TCP-11 interaction and the consequent modulation of AC/cAMP, which results in a stimulation of capacitation and an inhibition of spontaneous acrosome loss, could provide an important mechanism functioning in vivo to maximize the fertilizing potential of the very few spermatozoa that reach the upper regions of the uterine tubes where fertilization normally occurs.
Future prospects
Most investigations into mechanisms that might control sperm fertilizing ability have been conducted in vitro, where the conditions to which the spermatozoa are exposed can be carefully controlled. It is known that spermatozoa come into contact with FPP at ejaculation and that physiologically relevant concentrations of FPP elicit biologically important responses in vitro. Therefore, it is plausible that FPP would stimulate similar responses in vivo, although direct proof has yet to be obtained. Nevertheless, the identification of a molecule that modulates sperm function in vitro and might well do so in vivo may lead to development of new therapeutic treatments to improve the fertility of certain individuals. 'Male factor' infertility, which includes many different causes of sperm dysfunction, is clearly a contributor to infertility in many couples (ESHRE Capri Workshop, 1996) . In some instances the problems in achieving conception might be due to (1) insufficient concentrations of FPP, (2) the presence of FPP-related peptides unable to elicit the same responses as FPP, or (3) an alteration in the putative receptor TCP-11 and hence a reduced or absent response to FPP. Given that FPP-related peptides have either reduced or no biological action, compared with FPP, or may even act as a competitive inhibitor as appears to be the case with Gln-FPP, it may prove possible to supplement deficiencies of FPP. This could be done by addition of FPP to washed spermatozoa being prepared for intrauterine insemination or in vitro insemination or by incorporation of FPP into a cream or jelly inserted into the vagina. Alternatively, if a problem with TCP-11 can be identified, it would be possible to stimulate the spermatozoa at a step downstream of AC activation.
In addition to providing a rationale for the development of new therapeutic treatments for infertility, FPP ↔ TCP-11 could provide the target for a new approach to male contraception, designed to inhibit sperm function rather than sperm production. Considering that FPP was only established as a unique molecule in 1989, considerable progress has been made in identifying a function, a candidate receptor and a plausible mechanism of action for this tripeptide. Of particular importance is the fact that the various responses observed in vitro would be particularly relevant in vivo. If asked to design an ideal mechanism of action that would help to promote successful mammalian fertilization in vivo (knowing that few spermatozoa actually reach the site of fertilization), one probably would produce a mechanism that stimulated capacitation but inhibited spontaneous acrosome loss. FPP, working in conjunction with TCP-11, appears to do just that and this makes it a very exciting and biologically relevant system to investigate further.
